Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (2017 - 2025)

Cue Biopharma (CUE) has disclosed Shares Outstanding for 9 consecutive years, with $96.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 56.3% to $96.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.6 million through Dec 2025, up 56.3% year-over-year, with the annual reading at $96.6 million for FY2025, 56.3% up from the prior year.
  • Shares Outstanding hit $96.6 million in Q4 2025 for Cue Biopharma, up from $77.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $96.6 million in Q4 2025 to a low of $30.5 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $49.3 million across 5 years, with a median of $44.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding: grew 4.56% in 2021 and later skyrocketed 57.16% in 2025.
  • Year by year, Shares Outstanding stood at $32.2 million in 2021, then surged by 33.66% to $43.0 million in 2022, then rose by 9.69% to $47.2 million in 2023, then skyrocketed by 30.93% to $61.8 million in 2024, then soared by 56.3% to $96.6 million in 2025.
  • Business Quant data shows Shares Outstanding for CUE at $96.6 million in Q4 2025, $77.8 million in Q3 2025, and $76.4 million in Q2 2025.